NASDAQ:ADMA   ADMA Biologics Inc
SEC.gov The Company believes that a debt refinancing and expansion of its current debt facility, combined with the proceeds received from the foregoing public offering further discussed in Note 14, will be sufficient to fund its operations into the first quarter of 2024, at which time the Company believes its operations will be cash-flow positive. The Company is also evaluating a variety of strategic and financing alternatives and has engaged Morgan Stanley as a financial advisor in connection with certain of those strategic alternatives. There can be no assurances that the Company will be able to successfully refinance or expand its existing debt to obtain additional non-dilutive financing. These estimates may change based upon several factors, including the success of the Company’s commercial sales of its products, manufacturing ramp-up activities, the acceptability of ADMA’s immune globulin products by physicians, patients, or payers and the various financing options that may be available to the Company.